NCT04312594View on ClinicalTrials.gov

Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

June 9, 2022

Study Completion Date

June 9, 2022

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Jaktinib Hydrochloride Tablets

Patients were administered Jaktinib taken orally as tablets twice daily

DRUG

Jaktinib Hydrochloride Tablets

Patients were administered Jaktinib taken orally as tablets twice daily

DRUG

Placebo

Patients were administered Placebo taken orally as tablets twice daily

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT04312594 - Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis | Biotech Hunter | Biotech Hunter